RPL22P2

Across TCGA pan-cancer cohorts, RPL22P2 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of RPL22P2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where RPL22P2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL22P2 is over-expressed in tumor, although a few such as PRAD show the opposite, repressed pattern.

LUAD, THCA, and COAD are the cancer types where RPL22P2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL22P2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	II,III,IV	+1.178	<.001	9	view →
THCA	All	II,III,IV	+1.112	<.001	9	view →
COAD	Female	II,III,IV	+1.010	<.001	5	view →
HNSC	All	All	+0.215	.003	4	view →
KIRC	Male	All	+0.192	.031	2	view →
PRAD	All	All	−0.170	.029	2	view →
LUSC	All	All	+0.165	.018	2	view →
CHOL	All	All	+0.302	.024	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

RPL22P2–LUAD

Open the LUAD breakdown →